Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

NCT06660420 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Phase 1
Recurrent Melanoma
Refractory Melanoma

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

M.D. Anderson Cancer Center